WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2062
[post_author] => 3
[post_date] => 2015-11-23 20:09:45
[post_date_gmt] => 2015-11-23 20:09:45
[post_content] => Biotechnology Strategist Brian McCarthy and Pharma Executive Gian Luca Araldi
selected to launch new bioscience companies
STONY BROOK, N.Y. – November 23, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Brian McCarthy, PhD and Gian Luca Araldi, PhD, as BioEntrepreneurs-In-Residence (B-EIR) for the Long Island Bioscience Hub. The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions.
Drs. McCarthy and Araldi have broad bioscience industry experience and comprehensive knowledge of commercializing academic technologies. In their roles as BEIR they will identify technologies that have the potential to support company formation in the region. Each brings unique skills and perspectives to technology assessment and bioscience-startups.
Dr. McCarthy is a senior biotechnology strategist with operational, start-up, development, and financial expertise. He currently serves as a business advisor to Gismo Therapeutics Inc. and VP of Business and Clinical Development at Viatar CTC Solutions Inc. Prior to his Wall Street and entrepreneurial career, Dr. McCarthy was a faculty member at Cornell University Medical College and the National Naval Medical Center. Dr. McCarthy received his PhD in Neurobiology from Stony Brook University.
Dr. Araldi is a pharmaceutical and biotechnology executive with more than 25 years of experience ranging from basic research through clinical development at major pharmaceutical companies including Glaxo, Forest Laboratories and Merck-Serono. Dr. Araldi has been involved in the development of key medicines such as Teflaro®, Dutogliptin®, Gavestinel®, Sanfetrinem® and Sanfetrinem® Cilexetil and is the inventor of 113 granted patents. Dr. Araldi received doctorate degrees in Organic Chemistry and Pharmacy from the University of Parma (Italy) and recently received his M.B.A. in Finance from Long Island University Post.
“The Long Island Bioscience Hub is excited to announce the appointments of Drs. McCarthy and Araldi as BioEntrepreneurs-in-Residence” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “They join a talented roster of five existing BioEntrepreneurs in Residence at the Center for Biotechnology who are well on their way to commercializing technologies and building their companies.”
As B-EIRs Drs. McCarthy and Araldi are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation. They will have the support of the LIBH business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. The LIBH can also provide access to a competitive pool of technology development funding to help move their technologies down a commercial pathway. Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.
[post_title] => Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-bioscience-hub-selects-bioentrepreneurs-in-residence
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:13:28
[post_modified_gmt] => 2016-03-29 20:13:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2062
[menu_order] => 197
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4020
[post_author] => 4
[post_date] => 2023-01-26 14:48:11
[post_date_gmt] => 2023-01-26 14:48:11
[post_content] =>
Long Island New York I-Corps Hub - Innovation Bootcamp Spring 2023 Program
This Innovation Bootcamp Program will teach scientists, inventors and first-time entrepreneurs the Lean Launchpad Methodology – Customer Discovery through 20 interviews, Agile Development roadmapping, and the Business Model Canvas – specifically Value Propositions and Customer Segments
Kickoff Session: Tuesday, February 14, 9:00 AM - 4:00 PM (Online)
Mid Session: Friday, February 14, 9:15 AM - 4:00 PM (Online) and
Finale Session: Friday, March 3, 9:15 AM - 3:00 PM (Room 109, R&D Park Research and Support Services)
Applications are being reviewed NOW on a rolling basis until 11:59 PM Friday, Feb 3, 2023. Limited space is available - apply early! https://forms.gle/RM8WRrN3VuGVCMgP8
Teams of 1+ faculty, staff, etc. from any university, national lab, or community teams with an Innovation or Research Idea should be STEAM focused are encouraged to apply. Must be able to attend all 3 scheduled workshops and dedicate time outside of the sessions to do customer discovery interviews
For full details and eligibility requirements, please visit https://tinyurl.com/SBUBootcampSpring23
[post_title] => Call for Applications-Spring 2023 Innovation Bootcamp
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => call-for-applications-spring-2023-innovation-bootcamp
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-26 14:48:13
[post_modified_gmt] => 2023-01-26 14:48:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4020
[menu_order] => 9
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2499
[post_author] => 4
[post_date] => 2016-11-30 00:57:50
[post_date_gmt] => 2016-11-30 00:57:50
[post_content] => Third round of grants awarded for the development of commercially promising biomedical innovations
The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the third round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $550,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Eighteen months after its establishment, the LIBH has already awarded more than $2M to faculty innovators.
The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.
A wide range of disciplines are represented in the project awards this cycle including radiology, quantitative biology, biomedical engineering, chemistry, neurosurgery and cancer research. Nine Feasibility awards and one Proof of Concepts award have been funded this cycle. Projects awarded funding in this round include the development of radiotracers for use with PET scans to detect bacterial infections, specifically infective endocarditis (IE); a non-immune-based drug targeting amyloid ß-protein (Aß) for the treatment of mild Alzheimer's disease; DNA nano-carrier platform technology for targeted anti-thrombotic drug delivery in prosthetic heart valve and mechanical circulatory support patients; A medical device utilizing electrical and software engineering in order to detect congenital heart disease in newborn children, and profiling the human immune system through machine learning and bioinformatics. The full list of funded projects can be found on the LIBH webpage.
“The latest announcement of funded project for the LIBH demonstrates the volume of innovation housed within partner institutes that is primed to be moved out of the academic lab and into the commercial sector in order to help patients” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “It is exciting to witness our region’s innovators contemplating their research in ways they hadn’t before, and to see the vibrancy of the bioscience cluster on Long Island growing with each new project proposed.”
“Putting CSHL scientists together with HUB biotech entrepreneurs and industry reviewers is key to the successful translation of early stage ideas resulting from the basic research of Dr. Lingbo Zhang and Mickey Atwal, said Teri Willey, CSHL Vice President Business Development and Technology Transfer. “Zhang’s genetic research on myelodysplastic syndrome will be complimented by experience in medicinal chemistry. Similarly, Atwal’s work on developing therapeutics using physics and math to profile to the immune system will benefit from industry reviewers to guide it toward patient benefit."
“The success of the Long Island Bioscience Hub demonstrates the value of creative partnerships in bringing medical solutions that help address patients’ needs from the research lab to the doctor’s office and the medical clinic. We are proud to be part of the Bioscience Hub’s success,” said Kevin J. Tracey, M.D., President and CEO of the Feinstein Institute.
The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.
Download a PDF of the press release here.
[post_title] => Long Island Bioscience Hub Announces Additional Funded Projects
[post_excerpt] => The Long Island Bioscience Hub (LIBH), has announced funding for ten projects totaling $550,000 under the Hub’s technology development and commercialization initiative.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => long-island-bioscience-hub-announces-additional-funded-projects
[to_ping] =>
[pinged] =>
[post_modified] => 2017-01-09 15:08:10
[post_modified_gmt] => 2017-01-09 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2499
[menu_order] => 156
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 259
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
